US Patent

US8859562 — Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer

Method of Use · Assigned to University of Sheffield · Expires 2031-08-04 · 5y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of an agent that inhibits a specific enzyme for making a medicine to treat diseases caused by defective gene repair.

USPTO Abstract

The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2830 —
U-2655 —
U-2655 —
U-1634 — Lynparza
U-2273 — rucaparib-camsylate
U-2273 — rucaparib-camsylate
U-2655 —
U-2830 —
U-2012 — rucaparib-camsylate
U-2101 — Lynparza
U-2101 — Lynparza
U-2655 —

Patent Metadata

Patent number
US8859562
Jurisdiction
US
Classification
Method of Use
Expires
2031-08-04
Drug substance claim
No
Drug product claim
No
Assignee
University of Sheffield
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.